Cardiovascular Disease Diagnostics Solutions

Battling the number 1 cause of death worldwide with cardiovascular disease testing Comprehensive cardiac lab tests can support care for patients before and after adverse cardiac events

Successful management of cardiovascular diseases (CVD) means mitigating adverse events by making the right decisions. Clinicians want to diagnose and initiate appropriate treatment quickly to improve patient outcomes.

CVDs account for an estimated 31% of all deaths worldwide and are the number one cause of death globally, killing ~17.9 million people each year. Four out of five CVD deaths are due to heart attacks and strokes, while one third of these deaths occur prematurely in people under 70 years of age1 . The cost of CVDs globally is estimated to rise to $1,044 billion USD by 20302 .

Critical tests for acute care When every minute matters, speed and accuracy of results are paramount

Clinical laboratories can improve care for patients experiencing, or at risk for, cardiovascular disease. The speed and accuracy of the information your laboratory delivers are critical to improving patient outcomes and reducing the cost of care.

Beckman Coulter's comprehensive cardiac diagnostics menu provides the tests your laboratory needs to support informed clinical decision making.

Support Patients Experiencing, or at Risk for, Cardiovascular Disease

For Access 2 and DxI Series Analyzers

For AU and IMMAGE Series Analyzers

  • Apolipoprotein A-1
  • Apolipoprotein B
  • C-Reactive Protein, High Sensitivity
  • CK
  • CK-MB
  • HDL
  • Homocysteine
  • LDL
  • Lipoprotein(a)
  • TRIG
     

Access BNP reflects cardiac status and effects of therapy

B-type natriuretic peptide (BNP) is a protein secreted by the ventricular myocardium in response to volume or pressure overload and is an important biomarker in the diagnosis of heart failure (HF)3 . Achieve greater clinical insights to improve the management of heart failure patients across the disease spectrum from diagnosis to risk stratification and ongoing assessments of severity with Beckman Coulter’s Access BNP.

Learn more about Access BNP ›

Access hsTnI empowers earlier treatment in acute-care settings

Confidently report accurate results with the first true high-sensitivity troponin I assay cleared by the U.S. FDA. High-sensitivity troponin tests support more rapid decision making, which can help detect, triage and manage at-risk patients sooner4 and send acute myocardial infarction (AMI) low risk patients home faster5.

Learn how high-sensitivity troponin assays can improve patient outcomes ›

Access hsTnI detects circulating Troponin I, a protein released into circulation when there is damage to heart muscle cells. Primarily, hsTnI tests are used to help determine if an individual has suffered a heart attack (acute myocardial infarction). The use of hsTnI tests is more sensitive in detecting Troponin I quantities sooner and helps to give clinicians important insights into life-threatening cardiac conditions in patients presenting with chest pain, fast.

Learn more about Access hsTnI ›

Cutting ED triage time in half Access AccuTnI+3 provides fast, accurate information for better patient care

The clinical utility of cardiac troponin continues to evolve. Since the introduction of the first diagnostic cardiac troponin test nearly two decades ago, assay improvements have been quickly followed by changes in utility due to the unique sensitivity and specificity of cardiac troponin for cardiac injury.  

As the analytical performance of cardiac troponin continues to improve, better precision around the clinical decision point is enabling earlier rule-in and rule-out for non-ST-elevation AMI. Check out these resources to find out more about the cardiac troponin assay advantage:

Total laboratory solutions for cardiac care

Let us help you enhance your laboratory to support your patients' cardiovascular health management needs today and tomorrow. Contact us to get started.

Not available on IMMAGE Series Analyzers

1Cardiovascular diseases. (n.d.). Retrieved May 27, 2021, from Who.int website: https://www.who.int/health-topics/cardiovascular-diseases
2Institute for Health Metrics and Evaluation (IHME). The Global Burden of Diseases, Injuries and Risk Factors Study 2010 (GBD 2010). Generating Evidence, Guiding Policy Report
3Borke, J. Natriuretic Peptides in Congestive Heart Failure. March 9, 2021. Medscape. https://emedicine.medscape.com/article/761722-overview [Accessed: May 27, 2021]
4Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012; 33: 2252-7. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol, 2013; 61:1753-8.
5Storrow, AB et al. Diagnostic Performance of Cardiac Troponin I For Early Rule-in and Rule-out of Acute Myocardial Infarction: Results of a Prospective Multicenter Trial. Clinical Biochemistry, 2015; 48:254-259.